HRTX

HERON THERAPEUTICS, INC. /DE/

HRTX · CIK 818033 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20182025
Net Income−$20M
20182025
Operating CF−$28M
20182025
Free Cash Flow−$28M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue————————
Cost of Revenue$0.0B$0.0B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Gross Profit$0.1B$0.1B$0.1B——$0.0B$0.0B$0.0B
R&D Expense$0.0B$0.0B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.0B$-0.0B$-0.1B$-0.2B$-0.2B$-0.1B$-0.1B$-0.2B
Net Income$-0.0B$-0.0B$-0.1B$-0.2B$-0.2B$-0.1B$-0.1B$-0.0B
EPS (Basic)$-0.12$-0.09$-0.80$-1.67————
EPS (Diluted)$-0.12$-0.09$-0.80$-1.67————

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.3B$0.2B$0.2B$0.3B$0.3B$0.4B$0.5B$0.5B
Current Assets$0.2B$0.2B$0.2B$0.2B$0.3B$0.3B$0.5B$0.4B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B$0.1B$0.1B$0.1B$0.0B
Total Liabilities$0.2B$0.3B$0.3B$0.2B$0.2B$0.1B$0.1B—
Current Liabilities$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
Stockholders' Equity$0.0B$-0.0B$-0.0B$0.0B$0.1B$0.2B$0.4B$0.4B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.0B$-0.0B$-0.1B$-0.1B$-0.2B$-0.2B$-0.1B$-0.2B
Investing Cash Flow$0.0B$0.0B$0.0B$-0.0B$0.0B$0.2B$-0.0B$-0.3B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.1B$0.1B$0.2B$0.0B$0.2B$0.4B
← Companies